Clinical Trials Logo
  1. Home
  2. NSCLC, Stage I
  3. NCT04205552

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients — NEOpredict  

NSCLC, Stage I Clinical Trial

Official title:
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response

Clinical Trial Summary

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04205552
Study type Interventional
Source University Hospital, Essen
Contact Chiara Nicolini, PhD
Phone 0049 201 723 44708
Email chiara.nicolini@uk-essen.de
Status Recruiting
Phase Phase 2
Start date March 4, 2020
Completion date June 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05686434 - Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) Phase 2
Recruiting NCT04317534 - Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm Phase 2
Not yet recruiting NCT03446911 - Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery Phase 1/Phase 2
Not yet recruiting NCT06467383 - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting NCT04830826 - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting NCT06404164 - Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection N/A
Recruiting NCT03454685 - The Role of Microbiota on the Development of Lung Cancer
Enrolling by invitation NCT06028412 - Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study N/A
Recruiting NCT03446547 - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) Phase 2